ecancer

Immunology highlights from ASH 2014

Dr Catherine Bollard - George Washington University, Washington, USA

7 Dec 2014

Comment: T cell therapy for children with aggressive leukaemia

Dr Catherine Bollard - George Washington University, Washington, USA

7 Dec 2014

Comment: Blinatumomab for acute lymphocytic leukaemia

Dr Catherine Bollard - George Washington University, Washington, USA

7 Dec 2014

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma

Dr Catherine Bollard - George Washington University, Washington, USA

7 Dec 2014

ASH 2014: Expert discussion on the latest in CLL

Prof John Gribben and Prof Stephan Stilgenbauer

7 Dec 2014

Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma

Prof Amrita Krishnan - City of Hope National Medical Center, Los Angeles, USA

7 Dec 2014

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Dr Thomas Martin, MD, University of California, San Francisco, USA

7 Dec 2014

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study

Dr Thomas Martin, MD, University of California, San Francisco, USA

7 Dec 2014

HIV-associated lymphoma responds well to stem cell transplantation

Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA

7 Dec 2014

Relapsed multiple myeloma responds to combination therapy with daratumumab

Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain

7 Dec 2014

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study

Prof Marivi Mateos - University Hospital of Salamanca, Salamanca, Spain

7 Dec 2014

Stem cell transplantation safe for patients with HIV-associated lymphoma

Dr Joe Alvarnas - City of Hope National Medical Center, Los Angeles, USA

7 Dec 2014

More from ecancer